drugset / Trial / NCT04225871

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04225871

Phase 3 Active not recruiting 200 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelTreatment

Summary

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Timeline

Start
2019-12-23
Primary completion
2026-07-27
Completion
2026-07-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Zilucoplan Peptide 0.3 mg/kg Subcutaneous